Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -57.98% is 81% above its 2-year average of -312.00%, near the high end of its 2-year range (-607.00%–-57.98%).
84.99% above its 12-month average of -386.38%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.68%.
RETURN ON ASSETS (ROA)
-57.98%
RETURN ON ASSETS (ROA) AVG TTM
-386.38%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+84.99%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-79.84%
vs the sector median at left
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.18M
Return on Assets (ROA)
-57.98%
TTM Avg
-386.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.00M
Return on Assets (ROA)
-34.04%
TTM Avg
-20.59%
3Y Avg
-37.88%
5Y Avg
-37.10%
Market Cap
$104.48M
Return on Assets (ROA)
-33.85%
TTM Avg
-28.41%
3Y Avg
-17.06%
5Y Avg
-12.28%
Market Cap
$102.92M
Return on Assets (ROA)
-69.14%
TTM Avg
-63.05%
3Y Avg
-52.31%
5Y Avg
-58.69%
Market Cap
$105.48M
Return on Assets (ROA)
-16.87%
TTM Avg
-6.13%
3Y Avg
-6.48%
5Y Avg
-5.59%
Market Cap
$101.22M
Return on Assets (ROA)
7.36%
TTM Avg
-1.10%
3Y Avg
-3.18%
5Y Avg
2.66%
Market Cap
$106.18M
Return on Assets (ROA)
-70.09%
TTM Avg
-324.97%
3Y Avg
-229.15%
5Y Avg
-168.27%
Market Cap
$106.22M
Return on Assets (ROA)
-80.25%
TTM Avg
-36.24%
3Y Avg
-78.62%
5Y Avg
-77.58%
Market Cap
$107.41M
Return on Assets (ROA)
-233.43%
TTM Avg
-298.69%
3Y Avg
-252.88%
5Y Avg
-237.20%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.18M | -57.98% | -386.38% | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $104.00M | -34.04% | -20.59% | -37.88% | -37.10% |
| Definitive Healthcare Corp. (DH)vs › | $104.48M | -33.85% | -28.41% | -17.06% | -12.28% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.92M | -69.14% | -63.05% | -52.31% | -58.69% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $105.48M | -16.87% | -6.13% | -6.48% | -5.59% |
| The Joint Corp. (JYNT)vs › | $101.22M | 7.36% | -1.10% | -3.18% | 2.66% |
| Immunic, Inc. (IMUX)vs › | $106.18M | -70.09% | -324.97% | -229.15% | -168.27% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.22M | -80.25% | -36.24% | -78.62% | -77.58% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $107.41M | -233.43% | -298.69% | -252.88% | -237.20% |
| Vivani Medical, Inc. (VANI)vs › | $108.23M | -63.19% | -62.03% | -51.81% | -103.22% |
ROA
-58.0%
ROE
-62.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -165.77% |
| 2024-12-31 | -607.00% |
| 2023-12-31 | -163.24% |
